ReviewMikrochimica acta2025
SERS-powered precision: revolutionizing therapeutic drug monitoring with nanoscale sensitivity.
Review in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Emerging Plasmonic Nanomaterials for SERS-Based Disease Diagnostics: Innovations, Clinical Challenges, and AI Integration.Molecules (Basel, Switzerland) · 2026Review
- Design, Implementation, and Advances in Indirect SERS Sensors for Biomedical and Human-Health-Related Analyte Detection.Sensors (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Monitoring dynamic changes in drugs and their metabolites is essential for basic research, preclinical evaluation, and clinical applications. Surface-enhanced Raman spectroscopy (SERS) has shown great promise in therapeutic drug monitoring due to its high sensitivity, minimal sample consumption, non-destructive analysis, unique molecular fingerprints, and low cost. This review summarizes recent progress in SERS-baseand D-E]. For example,d drug monitoring, emphasizing novel substrate designs that improve detection sensitivity and selectivity. Key challenges, including poor signal reproducibility and interference from complex biological matrices, are discussed together with emerging strategies such as digital colloid-enhanced Raman spectroscopy, enrichment-based detection, microfluidic SERS, hybrid analytical platforms, and machine learning-assisted analysis. These approaches effectively address the limitations of conventional SERS and enhance analytical performance. Finally, future perspectives are outlined, highlighting the potential of integrating SERS with advanced technologies for targeted drug delivery, personalized therapy, and improved clinical outcomes.
Indexed as
Identifiers
41251787What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.